Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine ris...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Documents similaires